2024年10月27日 · Impact of MitraClip on Hospitalization Rates in Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation: Insights From RESHAPE-HF2

2024年11月21日 · CHICAGO, IL—Patients with stable CAD who respond well to the PCSK9 inhibitor evolocumab (Repatha; Amgen) have differences in gene expression compared with nonresponders, according to new data from the YELLOW III trial. Lead investigator Annapoorna Kini, MD (Icahn School of Medicine at Mount Sinai, New York, NY), told TCTMD the insights provided by transcriptomics—analysis of the RNA ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that ...

2024年10月28日 · Three secondary analyses clarified how the Impella pump works in STEMI with cardiogenic shock, and how things can go wrong.

2024年10月29日 · WASHINGTON, DC—Orbital atherectomy offers no advantages in treating severely calcified lesions over conventional balloon angioplasty before DES implantation, according to new data from the randomized ECLIPSE trial showing that the two options lead to comparable minimal stent area and 1-year target vessel failure. The trial only included lesions deemed crossable with a balloon by operators ...

TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.

2024年10月29日 · WASHINGTON, DC—In PEERLESS, the first randomized controlled trial pitting two different interventional strategies against each other in pulmonary embolism (PE), patients with acute intermediate-risk PE fared better over the short term if they received large-bore mechanical thrombectomy with the FlowTriever system (Inari Medical) rather than catheter-directed thrombolysis.

2024年10月27日 · TCT 399: HydroDynamic Contrast Recanalization (HDR): Initial Experience With a New Crossing Technique for Coronary Chronic Total Occlusions

2024年12月29日 · It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick succession by the US Food and Drug Administration, then later in 2024, long-awaited data broke new ground for the early treatment of severe aortic stenosis. In February, the Evoque tricuspid valve replacement system (Edwards Lifesciences) became the first transcatheter tricuspid ...

2024年8月28日 · Tirzepatide, when used for weight loss under the brand name Zepbound, is now more affordable thanks to a self-pay option created by the manufacturer, Lilly. The discount is available through the company’s own online pharmacy. The drug, an agonist of both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, has previously been sold ...